KGJI [KINGOLD JEWELRY] 8-K/A: (Original Filing)
[]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K/A: (Original Filing)
[PRIVATE & CONFIDENTIAL Our Ref: SCH 1623/SS/KK/A18/CH0589/16 April 28, 2016 Office of the Chief Accountant 100 F Street, NE USA Ladies and Gentlemen: We have read the statements regarding our firm contained in Items 4.01 and 4.02 of Form 8-K of Skystar Bio-Pharmaceutical Company dated and filed on April 6, 2016, and are in agreement with those statements. We hereby] []
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K/A: PRIVATE & CONFIDENTIAL Our Ref: SCH 1623/SS/KK/A18/CH0589/16 April
[PRIVATE & CONFIDENTIAL Our Ref: SCH 1623/SS/KK/A18/CH0589/16 April 28, 2016 Office of the Chief Accountant 100 F Street, NE USA Ladies and Gentlemen: We have read the statements regarding our firm contained in Items 4.01 and 4.02 of Form 8-K of Skystar Bio-Pharmaceutical Company dated and filed on April 6, 2016, and are in agreement with those statements. We hereby] []
KNDI [Kandi Technologies] 8-K/A: Correction: Kandi Technologies Reports Fourth Quarter and Full
[Correction: Kandi Technologies Reports Fourth Quarter and Full Year 2015 Financial Results Q4 EV parts sales increased 51.6% YoY to $57.5 million - 2015 EV parts sales increased 68.4% YoY to $196.1 million - Q4 the JV Company sold 12,100 EV products, a 231.0% increase YoY - JINHUA, CHINA-- (March 14, 2016) - Kandi Technologies Group, Inc. (the Company, we] [FORM 8-K (AMENDMENT NO. 1) CURRENT REPORT Date of Report (Date of earliest event reported): March 14, 2016 KANDI TECHNOLOGIES GROUP, INC. Delaware 001-33997 90-0363723 (State of Incorporation) (IRS Employer Identification) Jinhua City Industrial Zone Jinhua, Zhejiang Province Peoples Republic of China Post Code 321016 (86-579) 8223-9700 Item 2.02 Results of Operations and Financial Condition. Item 9.01. Description 99.1 Press]
TPI [TIANYIN PHARMACEUTICAL] 8-K/A: (Original Filing)
[TPI Received Acceptance Letter From NYSE MKT Regarding its Plan of Compliance with Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received a plan acceptance letter (the “Plan Acceptance Letter”) on January 5, 2016 from the] []
TPI [TIANYIN PHARMACEUTICAL] 8-K/A: TPI Received Acceptance Letter From NYSE MKT Regarding
[TPI Received Acceptance Letter From NYSE MKT Regarding its Plan of Compliance with Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received a plan acceptance letter (the “Plan Acceptance Letter”) on January 5, 2016 from the] []
SORL [SORL Auto Parts] 8-K/A: (Original Filing)
[SORL Auto Parts, Inc. 2ndQuarter FY2015 Financial Results Conference Call Event Date/Time: Aug 14, 2015 / 08:00AM EDT Participants Jin Rui Yu, Chief Operating Officer Min Con Lin, Accounting Manager Raymond Lin, IR Phyllis Huang, IR Kevin Theiss, Investor Relations Presentation Operator Greetings and welcome to the SORL Auto Parts 2015 second quarter conference call. At this time, all participants] []
